Aprea expects to report next APR-1051 clinical data update in Q4 2026
Company anticipates completing APR-1051 dose escalation and expansion in Q2 2027
Aprea expects cash and equivalents to fund operations into Q1 2028
Overview
US oncology drug developer reported Q2 net loss widened to $3.6 mln, or $0.07 per share
Cash and equivalents rose to $41.2 mln, boosted by $30 mln private placement
R&D expenses increased as company advanced Phase 1 APR-1051 trial and expanded enrollment
Result drivers
R&D expenses - Higher R&D costs driven by expanded enrollment and dose escalation in Phase 1 APR-1051 trial
Trial expansion - Accelerated enrollment and increase in active clinical sites for ACESOT-1051 trial
Early clinical activity - Early signs of activity for APR-1051, including partial responses and disease stabilization, prompted further trial expansion
Analyst coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
APRE•
